Medidata announced a multi-year partnership expansion with Catalyst Clinical Research to support their global oncology brand, Catalyst Oncology. This renewal builds upon Catalyst?s existing success with the Medidata Platform and incorporates wider offerings, including Medidata Grants Manager and Medidata AI Intelligent Trials, as Catalyst has grown into a robust and global full-service clinical research organization. This continued commitment for Medidata Rave EDC, Medidata Rave CTMS, and Medidata Rave eTMF enables Catalyst to run complex clinical trials while simplifying its operations and management.

By using these integrated capabilities, and incorporating the expansive elements of Grants Manager and Intelligent Trials, Catalyst can streamline workflows, automate document management, and improve visibility to critical trial metrics. Catalyst has supported over 150 oncology studies and is currently managing more than 80 next-generation cancer clinical trials now across Phases I-III. With 90% of all oncology approvals last year in the U.S. developed using Medidata software, Catalyst?s use of the Medidata Platform will be critical to their continued expansion.

In addition, Catalyst is excited to leverage Medidata AI, which accesses a dataset spanning more than 20 years to engage a more diverse patient population and accelerate enrollment.